IL154115A0 - Process for the preparation of growth hormone secretagogues - Google Patents

Process for the preparation of growth hormone secretagogues

Info

Publication number
IL154115A0
IL154115A0 IL15411598A IL15411598A IL154115A0 IL 154115 A0 IL154115 A0 IL 154115A0 IL 15411598 A IL15411598 A IL 15411598A IL 15411598 A IL15411598 A IL 15411598A IL 154115 A0 IL154115 A0 IL 154115A0
Authority
IL
Israel
Prior art keywords
preparation
growth hormone
hormone secretagogues
secretagogues
growth
Prior art date
Application number
IL15411598A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of IL154115A0 publication Critical patent/IL154115A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/78—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
IL15411598A 1997-06-25 1998-06-05 Process for the preparation of growth hormone secretagogues IL154115A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5079097P 1997-06-25 1997-06-25
IL13362698A IL133626A0 (en) 1997-06-25 1998-06-05 Treatment of insulin resistance with growth hormone secretagogues
PCT/IB1998/000876 WO1998058949A1 (en) 1997-06-25 1998-06-05 Treatment of insulin resistance with growth hormone secretagogues

Publications (1)

Publication Number Publication Date
IL154115A0 true IL154115A0 (en) 2003-07-31

Family

ID=21967444

Family Applications (7)

Application Number Title Priority Date Filing Date
IL15411598A IL154115A0 (en) 1997-06-25 1998-06-05 Process for the preparation of growth hormone secretagogues
IL13362698A IL133626A0 (en) 1997-06-25 1998-06-05 Treatment of insulin resistance with growth hormone secretagogues
IL15411698A IL154116A0 (en) 1997-06-25 1998-06-05 Sythesis of intermediates for the preparation of growth hormone secretagogues
IL15411198A IL154111A0 (en) 1997-06-25 1998-06-05 Synthesis of intermediates for the preparation of growth hormone secretagogues
IL15646598A IL156465A (en) 1997-06-25 1998-06-05 Growth hormone secretagogues for use in the treatment of sleep disorders
IL15411498A IL154114A0 (en) 1997-06-25 1998-06-05 Composition for use as a medicament for increasing levels of endogeneous growth hormone
IL15411298A IL154112A0 (en) 1997-06-25 1998-06-05 Synthesis of intermediates for the preparation of growth hormone secretagogues

Family Applications After (6)

Application Number Title Priority Date Filing Date
IL13362698A IL133626A0 (en) 1997-06-25 1998-06-05 Treatment of insulin resistance with growth hormone secretagogues
IL15411698A IL154116A0 (en) 1997-06-25 1998-06-05 Sythesis of intermediates for the preparation of growth hormone secretagogues
IL15411198A IL154111A0 (en) 1997-06-25 1998-06-05 Synthesis of intermediates for the preparation of growth hormone secretagogues
IL15646598A IL156465A (en) 1997-06-25 1998-06-05 Growth hormone secretagogues for use in the treatment of sleep disorders
IL15411498A IL154114A0 (en) 1997-06-25 1998-06-05 Composition for use as a medicament for increasing levels of endogeneous growth hormone
IL15411298A IL154112A0 (en) 1997-06-25 1998-06-05 Synthesis of intermediates for the preparation of growth hormone secretagogues

Country Status (40)

Country Link
US (3) US6448263B1 (oth)
EP (1) EP1000085B1 (oth)
JP (2) JP2000514099A (oth)
KR (1) KR20010014224A (oth)
CN (2) CN1530107A (oth)
AP (1) AP1145A (oth)
AR (1) AR012256A1 (oth)
AT (1) ATE305477T1 (oth)
AU (1) AU747510B2 (oth)
BG (1) BG104008A (oth)
BR (1) BR9810477A (oth)
CA (1) CA2294464A1 (oth)
CO (1) CO4950621A1 (oth)
DE (1) DE69831745T2 (oth)
DZ (1) DZ2539A1 (oth)
EA (1) EA002089B1 (oth)
EG (1) EG21712A (oth)
ES (1) ES2248899T3 (oth)
HN (1) HN1998000088A (oth)
HR (1) HRP980361A2 (oth)
HU (1) HUP0001922A3 (oth)
ID (1) ID24345A (oth)
IL (7) IL154115A0 (oth)
IN (1) IN189724B (oth)
IS (1) IS5275A (oth)
MA (1) MA24581A1 (oth)
NO (1) NO996205L (oth)
NZ (1) NZ500655A (oth)
OA (1) OA11242A (oth)
PA (1) PA8452601A1 (oth)
PE (1) PE105399A1 (oth)
PL (1) PL337659A1 (oth)
SK (1) SK175699A3 (oth)
TN (1) TNSN98113A1 (oth)
TR (1) TR199903257T2 (oth)
TW (1) TW553943B (oth)
UA (1) UA64751C2 (oth)
WO (1) WO1998058949A1 (oth)
YU (1) YU70199A (oth)
ZA (1) ZA985546B (oth)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA53716C2 (uk) 1997-06-25 2003-02-17 Пфайзер Продактс Інк. Тартратна сіль заміщеного дипептиду, спосіб її одержання, проміжні сполуки та спосіб їх одержання, фармацевтична композиція (варіанти), спосіб підвищення рівнів ендогенного гормону росту та спосіб лікування або профілактики захворювань (варіанти)
UA64751C2 (uk) 1997-06-25 2004-03-15 Пфайзер Продактс Інк. Спосіб лікування інсулінової толерантності речовинами, які посилюють секрецію гормону росту (варіанти) та фармацевтична композиція (варіанти)
US6541634B2 (en) * 1999-02-26 2003-04-01 Pfizer Inc. Process for preparing growth hormone secretagogues
US7721948B1 (en) * 1999-05-25 2010-05-25 Silverbrook Research Pty Ltd Method and system for online payments
EP1132388A3 (en) * 2000-03-09 2004-03-03 Pfizer Products Inc. Hexahydropyrazolo[4,3-c]pyridine metabolites
ES2333097T3 (es) 2000-05-31 2010-02-17 Raqualia Pharma Inc Uso de secretagogos de la hormona de crecimiento para estimular la motilidad gastrointestinal.
IL145106A0 (en) * 2000-08-30 2002-06-30 Pfizer Prod Inc Intermittent administration of a geowth hormone secretagogue
MXPA05002991A (es) * 2002-09-18 2005-10-05 Univ Montreal Ct Hospitalier Chum Analogos de ghrh.
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
JP2008524427A (ja) * 2004-12-21 2008-07-10 ハーキュリーズ・インコーポレーテッド 亜硫酸イオンを含む製紙系において乾燥および湿潤紙力増強剤として使用するための反応性を有するカチオン性樹脂
US20070024388A1 (en) * 2005-07-27 2007-02-01 Hassan Tanbakuchi Slabline structure with rotationally offset ground
CU23558A1 (es) 2006-02-28 2010-07-20 Ct Ingenieria Genetica Biotech Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento
EA200901077A1 (ru) 2007-02-09 2010-04-30 Транзим Фарма, Инк. Макроциклические модуляторы грелинового рецептора и их применение
US7862825B2 (en) * 2007-02-21 2011-01-04 Mladen Vranic Method of controlling tight blood glucose by somatostatin receptor antagonists
RU2403902C1 (ru) * 2009-06-15 2010-11-20 Илья Николаевич Медведев Способ снижения биологического возраста при нарушении толерантности к глюкозе
US8546416B2 (en) 2011-05-27 2013-10-01 Novartis Ag 3-spirocyclic piperidine derivatives as ghrelin receptor agonists
TW201348235A (zh) 2012-05-03 2013-12-01 Novartis Ag 作爲格瑞啉受體促效劑之３－螺環哌啶衍生物
RU2670978C9 (ru) * 2013-05-28 2018-11-22 Раквалиа Фарма Инк. Полиморфные формы
US9119832B2 (en) 2014-02-05 2015-09-01 The Regents Of The University Of California Methods of treating mild brain injury
CN106459147B (zh) * 2014-08-05 2021-08-06 拉夸里亚创药株式会社 作为生长激素释放肽受体激动剂的丝氨酸衍生物
KR20170078612A (ko) * 2014-10-31 2017-07-07 라퀄리아 파마 인코포레이티드 그렐린 수용체 효능제로서 테트라히드로피라졸로피리딘 유도체
US20170121385A1 (en) 2015-10-28 2017-05-04 Oxeia Biopharmaceuticals, Inc. Methods of treating neurodegenerative conditions
CN120265641A (zh) * 2023-04-21 2025-07-04 长春金赛药业有限责任公司 GHSR 1a激动剂、药物组合物及其制备方法和应用
CN119285632A (zh) * 2024-10-09 2025-01-10 威海中腾医药科技有限公司 一种基于酵母醇脱氢酶催化氧化的卡普瑞林中间体的制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3235550A (en) 1966-02-15 Anal g gesiaxoat t tail intravenous injection
US3202660A (en) 1961-10-09 1965-08-24 Boehringer Sohn Ingelheim Process for the preparation of 3-arylamino-1, 3-diazacycloalkenes
US4411890A (en) 1981-04-14 1983-10-25 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
GB2101114B (en) 1981-07-10 1985-05-22 Farmos Group Ltd Substituted imidazole derivatives and their preparation and use
US5242783A (en) 1991-07-31 1993-09-07 Eastman Kodak Company Photographic material and process
JPH08503213A (ja) 1992-11-06 1996-04-09 メルク エンド カンパニー インコーポレーテッド 成長ホルモンの放出を促進する置換ジペプチド同族体
RO115804B1 (ro) 1992-12-11 2000-06-30 Merck & Co Inc Derivati de spiropiperidine, procedee de preparare si compozitii farmaceutice ale acestora
CZ134296A3 (en) 1993-11-09 1996-12-11 Merck & Co Inc Piperidine, pyrrolidine and hexahydro-1h-azepine derivatives, process of their preparation and pharmaceutical compositions containing thereof
US5492916A (en) * 1993-12-23 1996-02-20 Merck & Co., Inc. Di- and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
BR9610277A (pt) 1995-08-31 1999-07-06 Schering Corp Derivados de piperazino como antagonistas de neurowuinina
EP0766966A3 (en) * 1995-09-08 2001-02-28 Eli Lilly And Company Method of treating insulin resistance
CA2239711A1 (en) 1995-12-22 1997-07-03 Novo Nordisk A/S Compounds with growth hormone releasing properties
TW432073B (en) 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
UA53716C2 (uk) 1997-06-25 2003-02-17 Пфайзер Продактс Інк. Тартратна сіль заміщеного дипептиду, спосіб її одержання, проміжні сполуки та спосіб їх одержання, фармацевтична композиція (варіанти), спосіб підвищення рівнів ендогенного гормону росту та спосіб лікування або профілактики захворювань (варіанти)
ATE356139T1 (de) * 1997-06-25 2007-03-15 Pfizer Dipeptidderivate zur förderung der sekretion von wachstumshormon
UA64751C2 (uk) 1997-06-25 2004-03-15 Пфайзер Продактс Інк. Спосіб лікування інсулінової толерантності речовинами, які посилюють секрецію гормону росту (варіанти) та фармацевтична композиція (варіанти)

Also Published As

Publication number Publication date
IL154111A0 (en) 2003-07-31
IL154116A0 (en) 2003-07-31
HRP980361A2 (en) 1999-02-28
CN1259140A (zh) 2000-07-05
DE69831745T2 (de) 2006-08-31
TR199903257T2 (xx) 2000-12-21
CN1152049C (zh) 2004-06-02
YU70199A (sh) 2003-01-31
ID24345A (id) 2000-07-13
PA8452601A1 (es) 2000-05-24
US6630487B2 (en) 2003-10-07
ATE305477T1 (de) 2005-10-15
KR20010014224A (ko) 2001-02-26
NO996205D0 (no) 1999-12-15
IN189724B (oth) 2003-04-19
EP1000085B1 (en) 2005-09-28
BR9810477A (pt) 2007-05-22
HN1998000088A (es) 1999-01-08
EG21712A (en) 2002-02-27
JP2000514099A (ja) 2000-10-24
BG104008A (en) 2000-07-31
US6448263B1 (en) 2002-09-10
ZA985546B (en) 2000-01-10
PL337659A1 (en) 2000-08-28
IL154114A0 (en) 2003-07-31
IL156465A0 (en) 2004-01-04
AP1145A (en) 2003-02-14
TNSN98113A1 (fr) 2005-03-15
WO1998058949A1 (en) 1998-12-30
ES2248899T3 (es) 2006-03-16
US6867202B1 (en) 2005-03-15
EA002089B1 (ru) 2001-12-24
AU7445698A (en) 1999-01-04
IS5275A (is) 1999-11-26
NO996205L (no) 1999-12-15
EA199901075A1 (ru) 2000-08-28
IL156465A (en) 2004-07-25
CN1530107A (zh) 2004-09-22
AU747510B2 (en) 2002-05-16
AP9801267A0 (en) 1998-06-30
CO4950621A1 (es) 2000-09-01
JP2005097261A (ja) 2005-04-14
DZ2539A1 (fr) 2003-02-08
TW553943B (en) 2003-09-21
HK1028051A1 (en) 2001-02-02
MA24581A1 (fr) 1998-12-31
JP3742643B2 (ja) 2006-02-08
NZ500655A (en) 2002-02-01
US20030100561A1 (en) 2003-05-29
AR012256A1 (es) 2000-09-27
SK175699A3 (en) 2001-04-09
HUP0001922A2 (hu) 2000-12-28
IL154112A0 (en) 2003-07-31
UA64751C2 (uk) 2004-03-15
DE69831745D1 (de) 2006-02-09
EP1000085A1 (en) 2000-05-17
PE105399A1 (es) 1999-11-04
OA11242A (en) 2003-07-23
HUP0001922A3 (en) 2001-02-28
CA2294464A1 (en) 1998-12-30
IL133626A0 (en) 2001-04-30

Similar Documents

Publication Publication Date Title
IL154115A0 (en) Process for the preparation of growth hormone secretagogues
AU6772996A (en) 2-acylaminopropanamides as growth hormone secretagogues
AP9901555A0 (en) Dipeptide compounds which are growth hormone secretagogues
IL134596A0 (en) Growth hormone secretagogues
IL129759A0 (en) Process for the preparation of benzyl-ethers
AU6724496A (en) 2-acylaminopropanamines as growth hormone secretagogues
GB9504711D0 (en) Process for the preparation of chloropyrimidines
ZA9810669B (en) Process for the preparation of 8-methoxy-quinolone-carbyxylic acids
GR3036917T3 (en) Process for the preparation of pyrimidine compounds
HU9904384D0 (en) Process and intermediates for growth hormone secretagogues
IL121730A0 (en) Process for the preparation of 2'-fluoro-5-methyl-beta-L-arabino-furanosyluridine
HUP9902095A3 (en) New process for the preparation of a growth hormone secretagogue
IL133140A0 (en) Novel process for the preparation of 4-aryl-piperidines
EP1126854A4 (en) BENZOAZEPINES AND THEIR ANALOGS AS MEANS THAT PROMOTE THE SECRETION OF THE GROWTH HORMONE
GB9823422D0 (en) Naptho-fused lactams promate release of growth hormone
IL128026A0 (en) Process for the preparation of hexanitrohexa-azaisowurtzitanes
AP2000001754A0 (en) Process for preparing growth hormone secretagogues
ZA987741B (en) Process for the preparation of oxazaphosphorine-2-amines
IL120715A0 (en) Process for the preparation of trifluoroethoxy-arenecarboxylic acids
HUP0001757A3 (en) Improved process for the preparation of halo-4-phenoxyquinolines
GR3035436T3 (en) Process for the preparation of 2-H-heptafluoropropane
ZA989241B (en) Process for the preparation of azacycloalkylalkanoyl pseudotetrapeptides
EP0831156A4 (en) 3-ALCOXYMETHYLCEPHEMS PREPARATION PROCESS
GB9807032D0 (en) Process for the preparation of (S)-3-carbethoxy-3-benzylpiperidine
IL116759A0 (en) Process for the preparation of para-fluorophenol